ALKERMES INC Form 10-Q August 14, 2006

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### Form 10-Q

(Mark One)

- **DESCRIPTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** 
  - For the quarterly period ended June 30, 2006
- o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

#### Commission file number 1-14131

#### ALKERMES, INC.

(Exact name of registrant as specified in its charter)

#### **PENNSYLVANIA**

23-2472830

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

## 88 Sidney Street, Cambridge, MA

02139-4234

(Address of principal executive offices)

(Zip Code)

# Registrant s telephone number including area code: (617) 494-0171

(Former name, former address, and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes b No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of accelerated filer and large accelerated filer in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer b Accelerated filer o Non-accelerated filer o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.): Yes o No b

The number of shares outstanding of each of the issuer s classes of common stock was:

 Class
 As of July 31, 2006

 Common Stock, \$.01 par value
 100,922,394

382,632

Non-Voting Common Stock, \$.01 par value

# ALKERMES, INC. AND SUBSIDIARIES

# **INDEX**

		Page No
	PART I FINANCIAL INFORMATION	
Item 1.	Unaudited Condensed Consolidated Financial Statements:	
	Condensed Consolidated Balance Sheets June 30, 2006 and March 31, 2006	3
	Condensed Consolidated Statements of Operations For the Three Months Ended	
	June 30, 2006 and 2005	4
	Condensed Consolidated Statements of Cash Flows For the Three Months Ended	
	June 30, 2006 and 2005	5
	Notes to Unaudited Condensed Consolidated Financial Statements	6
Item 2.	Management s Discussion and Analysis of Financial Condition and Results of	
	<u>Operations</u>	14
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	21
Item 4.	Controls and Procedures	22
	PART II OTHER INFORMATION	
Item 1A.	Risk Factors	24
Item 2.	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	25
Item 5.	Other Information	25
Item 6.	<u>Exhibits</u>	25
<u>Signatures</u>		26
Exhibit Index:		27
Ex-31.1 Certification		
Ex-31.2 Certification		
Ex-32.1 Certification	s of CEO & CFO pursuant to Section 906	
	2	

## **PART 1. FINANCIAL INFORMATION**

## Item 1. Unaudited Condensed Consolidated Financial Statements:

# ALKERMES, INC. AND SUBSIDIARIES

## CONDENSED CONSOLIDATED BALANCE SHEETS

	•	June 30, 2006 (In thousa share and amo	share	
ASSETS				
CURRENT ASSETS:				
Cash and cash equivalents	\$	107,923	\$	33,578
Investments short-term		260,616		264,389
Receivables		41,353		39,802
Inventory, net		11,378		7,341
Prepaid expenses and other current assets		4,802		2,782
Total current assets		426,072		347,892
PROPERTY, PLANT AND EQUIPMENT:				
Land		301		301
Building and improvements		21,186		20,966
Furniture, fixtures and equipment		63,752		61,086
Equipment under capital lease		464		464
Leasehold improvements		45,971		45,842
Construction in progress		27,158		23,555
		158,832		152,214
Less: accumulated depreciation and amortization		(42,586)		(39,297)
Property, plant and equipment net		116,246		112,917
RESTRICTED INVESTMENTS long-term		5,145		5,145
OTHER ASSETS		10,290		11,209
TOTAL ASSETS	\$	557,753	\$	477,163
LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND SCURRENT LIABILITIES:	SHA	REHOLDI	ERS	EQUITY
Accounts payable and accrued expenses	\$	28,992	\$	36,141

Accrued interest Accrued restructuring costs Unearned milestone revenue current portion Deferred revenue current portion Convertible subordinated notes current portion Long-term debt current portion	2,985 855 56,320 200 676 1,239	3,239 852 83,338 200 676 1,214
Total current liabilities	91,267	125,660
NON-RECOURSE RISPERDAL CONSTA SECURED 7% NOTES CONVERTIBLE SUBORDINATED NOTES LONG-TERM PORTION LONG-TERM DEBT UNEARNED MILESTONE REVENUE LONG-TERM PORTION DEFERRED REVENUE LONG-TERM PORTION OTHER LONG-TERM LIABILITIES	1,200 124,319 700 6,677	153,653 124,346 1,519 16,198 750 6,821
TOTAL LIABILITIES	378,590	428,947
REDEEMABLE CONVERTIBLE PREFERRED STOCK, par value, \$0.01 per share; authorized and issued, 1,500 shares at June 30, 2006 and March 31, 2006 (at liquidation preference)  COMMITMENTS AND CONTINGENCIES  SHAREHOLDERS EQUITY:  Capital stock, par value, \$0.01 per share; authorized, 4,550,000 shares (includes 2,997,000 shares of preferred stock); issued, none  Common stock, par value, \$0.01 per share; authorized, 160,000,000 shares;	15,000	15,000
101,041,464 and 91,744,680 shares issued, 100,906,834 and 91,744,680 shares outstanding at June 30, 2006 and March 31, 2006, respectively  Nonvoting common stock, par value, \$0.01 per share; authorized 450,000 shares;	1,010	917
issued and outstanding, 382,632 shares at June 30, 2006 and March 31, 2006 Treasury stock, at cost (134,630 and 0 shares at June 30, 2006 and March 31, 2006,	(2.627)	4
respectively) Additional paid-in capital Deferred compensation	(2,627) 798,084	664,596 (374)
Accumulated other comprehensive income Accumulated deficit	1,398 (633,706)	1,064 (632,991)
Total shareholders equity	164,163	33,216
TOTAL LIABILITIES, REDEEMABLE CONVERTIBLE PREFERRED STOCK AND SHAREHOLDERS EQUITY	\$ 557,753	\$ 477,163

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

# ALKERMES, INC. AND SUBSIDIARIES

## CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	Three Months Ended June 30, 2006 (In thousan share		nds, e	
REVENUES: Manufacturing revenues Royalty revenues Research and development revenue under collaborative arrangements Net collaborative profit	\$	22,193 5,139 14,464 9,742	\$	13,983 3,604 7,251
Total revenues		51,538		24,838
EXPENSES: Cost of goods manufactured Research and development Selling, general and administrative		9,338 25,863 16,530		4,517 21,622 8,952
Total expenses		51,731		35,091
OPERATING LOSS		(193)		(10,253)
OTHER INCOME (EXPENSE): Interest income Interest expense Derivative loss related to convertible subordinated notes Other income (expense), net		4,335 (5,473) 787		1,631 (5,169) (266) 320
Total other income (expense)		(351)		(3,484)
LOSS BEFORE INCOME TAXES INCOME TAXES		(544) 171		(13,737)
NET LOSS	\$	(715)	\$	(13,737)
LOSS PER COMMON SHARE, BASIC AND DILUTED	\$	(0.01)	\$	(0.15)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING, BASIC AND DILUTED		93,784		90,410

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

4

# ALKERMES, INC. AND SUBSIDIARIES

## CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

	M I Ju	Three Months Ended June 30, 2006 (In the		Three Months Ended June 30, 2005 nousands)	
CASH FLOWS FROM OPERATING ACTIVITIES:					
Net loss	\$	(715)	\$	(13,737)	
Adjustments to reconcile net loss to net cash provided by operating activities:					
Depreciation and amortization		2,826		2,578	
Stock-based compensation		8,347		58	
Other non-cash charges		1,215		1,303	
Derivative loss related to convertible subordinated notes				266	
Gain on investments		(846)		(308)	
Loss on sale of equipment		5			
Changes in assets and liabilities:					
Receivables		(1,551)		(9,004)	
Inventory, prepaid expenses and other current assets		(5,401)		(776)	
Accounts payable, accrued expenses and accrued interest		(7,370)		1,006	
Accrued restructuring costs		(159)		(322)	
Unearned milestone revenue		81,103		160,000	
Deferred revenue		(50)		100	
Other long-term liabilities		18		108	
Net cash provided by operating activities		77,422		141,272	
CASH FLOWS FROM INVESTING ACTIVITIES:					
Additions to property, plant and equipment		(6,160)		(5,301)	
Proceeds from the sale of equipment				1	
Purchases of short and long-term investments		(63,374)		(326,173)	
Sales and maturities of short and long-term investments		67,096		165,431	
Decrease in other assets		14		18	
Net cash used in investing activities		(2,424)		(166,024)	
CASH FLOWS FROM FINANCING ACTIVITIES:					
Proceeds from issuance of common stock		2,268		351	
Payment of debt		(294)		(273)	
Purchase of treasury stock		(2,627)			
Net cash (used in) provided by financing activities		(653)		78	
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS		74,345		(24,674)	

Edgar Filing: ALKERMES INC - Form 10-Q

CASH AND CASH EQUIVALENTS	Beginning of period	33,578	47,485
CASH AND CASH EQUIVALENTS	End of period	\$ 107,923	\$ 22,811
SUPPLEMENTARY INFORMATION Cash paid for interest Noncash activities:	:	\$ 4,511	\$ 2,057
Conversion of 2.5% convertible subord	inated notes into common stock	\$ 125,000	\$

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

5

#### ALKERMES, INC. AND SUBSIDIARIES

#### NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

#### 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

#### **Basis of Presentation**

The accompanying condensed consolidated financial statements of Alkermes, Inc. (the Company or Alkermes) for the three months ended June 30, 2006 and 2005 are unaudited and have been prepared on a basis substantially consistent with the audited financial statements for the year ended March 31, 2006. In the opinion of management, the condensed consolidated financial statements include all adjustments that are necessary to present fairly the results of operations for the reported periods. The Company s condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America (commonly referred to as GAAP).

These financial statements should be read in conjunction with the Company s audited consolidated financial statements and notes thereto which are contained in the Company s Annual Report on Form 10-K/A for the year ended March 31, 2006, filed with the Securities and Exchange Commission (SEC).

The results of the Company s operations for any interim period are not necessarily indicative of the results of the Company s operations for any other interim period or for a full fiscal year.

Principles of Consolidation The unaudited condensed consolidated financial statements include the accounts of Alkermes, Inc. and its wholly-owned subsidiaries: Alkermes Controlled Therapeutics, Inc. ( ACT I ); Alkermes Controlled Therapeutics, Inc. ( ACT I ); Alkermes Acquisition Corp.; Alkermes Europe, Ltd.; Advanced Inhalation Research, Inc. ( AIR ); and RC Royalty Sub LLC ( Royalty Sub ). Intercompany accounts and transactions have been eliminated. The assets of Royalty Sub are not available to satisfy obligations of Alkermes and its subsidiaries, other than the obligations of Royalty Sub including Royalty Sub s non-recourse RISPERDAL CONSTA secured 7% notes (the Non-Recourse 7% Notes ).

Use of Estimates The preparation of the Company s unaudited condensed consolidated financial statements in conformity with GAAP necessarily requires management to make estimates and assumptions that affect the following: (1) reported amounts of assets and liabilities; (2) disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements; and (3) the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

#### New Accounting Pronouncements

Effective April 1, 2006, the Company adopted the provisions of Statement of Financial Accounting Standards (SFAS) No. 151, *Inventory Costs* (SFAS 151), which amends Accounting Research Bulletin (ARB) No. 43, Chapter 4, *Inventory Pricing*, to clarify the accounting for idle facility expense, freight, handling costs and waste (spoilage). Adoption of SFAS 151 did not have a material impact on the unaudited condensed consolidated financial statements.

Effective April 1, 2006, the Company adopted the provisions of SFAS No. 123(R), *Share-Based Payment* (SFAS 123R). See Note 8.

In July 2006, the Financial Accounting Standards Board (FASB) issued FASB Interpretation (FIN) No. 48, *Accounting for Uncertainty in Income Taxes* (FIN No. 48), an interpretation of SFAS No. 109, *Accounting for Income Taxes*. FIN No. 48 clarifies the accounting for uncertainty in income taxes recognized in a company s financial

statements and prescribes a recognition threshold and measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. FIN No. 48 also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition and will become effective for the Company on April 1, 2007. The Company is in the process of evaluating the impact of adoption of FIN No. 48.

6

# ALKERMES, INC. AND SUBSIDIARIES

# NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

## 2. COMPREHENSIVE LOSS

Comprehensive loss for the three months ended June 30, 2006 and 2005 is as follows:

(In thousands)	Three Months Ended June 30, 2006			Three Months Ended June 30, 2005	
Net loss Unrealized gain on marketable securities	\$	(715) 334	\$	(13,737) 136	
Comprehensive loss	\$	(381)	\$	(13,601)	

## 3. LOSS PER COMMON SHARE

Basic loss per common share was calcul